香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 名稱： 點金系列看跌兩層區間24天結構性 存款 結構性存款（掛鈎匯率三層區間A款） Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2251） 有關認購結構性存款之須予披露及主要交易 結構性存款的主要條款 招商銀行結構性存款 廈門國際銀行結構性存款 認購實體： 本公司、北京鷹瞳及上海鷹瞳 北京智能科技 有關認購結構性存款之須予披露及主要交易 及 截至2024年6月30日止六個月之中期業績公告的補充公告 董事會宣佈，於2022年1月14日至2024年7月4日期間，本集團認購招商銀行結構性 存款及廈門國際銀行結構性存款，以作現金及財資管理之用。截至本公告日期，本 集團已贖回所有上述結構性存款。 結構性存款的主要條款載列如下： 招商銀行結構性存款 | --- | --- | --- | |------ ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2251） 有關本公司截至2023年12月31日止年度之年報的補充公告 緒言 茲提述北京鷹瞳科技發展股份有限公司（「本公司」）於2024年4月25日刊登於香港聯 合交易所有限公司（「聯交所」）及本公司網站的截至2023年12月31日止年度之2023年 年報（「2023年年報」）。除另有說明外，本公告所用詞彙與2023年年報所界定者具有 相同涵義。 除2023年年報內提供的資料外，本公司謹此根據上市規則附錄D2第32(4)及32(4A) 段，於2023年年報「重大投資、重大收購及出售事項」一段向股東及本公司潛在投資 者提供額外資料。 – 1 – 截至2023年12月31日，本集團持有若干投資及理財產品，其價值佔本集團資產總值 之5%或以上，詳情載列如下 ...

Q Airdoc鹰瞳 Beijing Airdoc Technology Co , Ltd 北京鷹瞳科技發展股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liability) (於中華人民共和國註冊成立的股份有限公司) Stock Code 股份代號：2251 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------|-------|-------|-------|----------------|----------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2024 | | | | | | | | | | Interim Report | | | | | | | | | | | | | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部份內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2251） 中期業績公告 截至2024年6月30日止六個月 本公司董事會欣然宣佈本集團截至2024年6月30日止六個月的未經審核簡明綜合中期業 績，連同2023年同期的比較數字如下。該等中期業績已經審核委員會及本公司核數師安 永會計師事務所審閱。 於本公告內，「我們」指本公司，及如文義另有所指，指本集團。本公告所載若干金額及 百分比數字已約整，或已四捨五入至小數點後一位或兩位。任何表格、圖表或其他部分 所示總額與所列數額總和的任何差異乃因約整所致。 – 1 – | --- | --- | --- | |----------------------------|--------------|--------------| | | | | | 財務概要 ...

Proprietary AI-empowered Hardware Devices 20 BEIJING AIRDOC TECHNOLOGY CO., LTD. Annual Report 2023 During the Reporting Period, our technology aided in the early screening and treatment of Alzheimer's Disease ("AD"). China Life Property & Casualty Insurance launched the first specific disease insurance product in China that can be purchased even by individuals who have been diagnosed with AD. This product includes our AI-based retinal screening service as a value-added service, providing the insured popula ...

证 券 研 究 报 告 请务必阅读免责条款 一般声明 特别声明 分析员声明 国元国际控股有限公司 香港中环康乐广场 8 号交易广场三期 17 楼 电话：(852)37696888 传真：(852)37696999 服务热线：400-888-1313 公司网址：http://www.gyzq.com.hk | --- | --- | |---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 年度業績公告 截至2023年12月31日止年度 於本公告內，「我們」指本公司，或如文義另有所指，指本集團。本公告所載若干金額及 百分比數字已約整，或已四捨五入至小數點後一位或兩位。任何表格、圖表或其他部分 所示總額與所列數額總和的任何差異乃因約整所致。 財務概要 – 2 – • 2023年，我們通過SaMD和健康風險評估解決方案共計服務了6.83百萬病例，識別出 31,459例重大陽性案例，活躍服務網點數增長到5,671，同比增長139.2%，客戶數量 增長至673個，同比增長69.5%。 • 為了推進從檢測到診療一體化的戰略規劃，我們在報告期內擴大了產品組合，納入 近視防控AI產品和視覺訓練AI產品。其中，我們的近視防控AI產品使用次數達到 89.03萬，服務用戶數量達到1.4萬；視覺訓練AI產品訓練次數達到了91.84萬，家庭 訓練服務用戶數量達到1.3萬，到院訓練服務用戶數量達到8.1萬，並且，我 ...

Our R&D expenses decreased by 18.8% from RMB69.6 million for the six months ended June 30, 2022 to RMB56.5 million for the six months ended June 30, 2023, primarily due to the decrease in employee benefits expenses as we continue to streamline corporate operations and prioritize targeted R&D activities. Our revenue increased by 120.6% from RMB37.4 million for the six months ended June 30, 2022 to RMB82.5 million for the six months ended June 30, 2023. The increase is primarily attributable to (i) a 137% yea ...

其他收入及收益 我們的其他收入及收益由截至2022年6月30日止六個月的人民幣28.6百萬元增加至截至 2023年6月30日止六個月的人民幣49.8百萬元，主要由於資金管理回報提高所致。 – 15 – 研發開支 我們的研發開支主要包括(i)研發僱員的僱員福利開支；(ii)產品開發開支，包括人工智能 研究、研發活動、技術服務、醫療設備及測試服務產生的開支；(iii)產品註冊開支；(iv) 與我們的研發設備和設施有關的折舊開支；及(v)其他，主要包括我們研發設施的租賃開 支、研發活動相關的差旅開支、水電費及其他一般辦公開支。下表概列於所示期間我們 的研發開支明細。 | --- | --- | --- | |--------------|---------------------|-------------------------| | | 截至 6 月 \n2023 年 | 30 日止六個月 \n2022 年 | | | （未經審核） | （未經審核） | | | 人民幣千元 | 人民幣千元 | | | | | | 僱員福利開支 | 39,809 | 47,771 | | 產品開發開支 | 8,529 | 13, ...

Financial Performance - Revenue for 2022 was 113,657 thousand RMB, a decrease of 1.3% compared to 115,181 thousand RMB in 2021[1] - Operating loss for 2022 was 182,301 thousand RMB, an increase of 28.2% compared to 142,229 thousand RMB in 2021[1] - Gross profit decreased from RMB 70.2 million in 2021 to RMB 55.9 million in 2022, with overall gross margin dropping from 61.0% to 49.1%, while AI software solutions maintained a 64.0% gross margin[28] - R&D expenses increased by 95.4% from RMB 64.3 million in 2021 to RMB 125.6 million in 2022, driven by team expansion and investments in AI software solutions and hardware products[31] - Sales expenses rose by 37.8% from RMB 72.6 million in 2021 to RMB 100.0 million in 2022, primarily due to the expansion of the sales and marketing team[32] - The company recorded a loss of RMB 182.7 million in 2022, compared to a loss of RMB 142.5 million in 2021[35] - Pre-tax loss for the year ending December 31 was RMB 182,740 thousand, compared to RMB 142,527 thousand in the previous year[174] - Gross profit for 2022 was RMB 55.852 million, compared to RMB 70.241 million in 2021, RMB 29.087 million in 2020, and RMB 16.107 million in 2019[192] Assets and Liabilities - Non-current assets increased to 64,137 thousand RMB in 2022, up 32.1% from 48,566 thousand RMB in 2021[2] - Current assets decreased to 1,675,818 thousand RMB in 2022, down 9.2% from 1,845,611 thousand RMB in 2021[2] - Inventory increased from RMB 7.7 million in 2021 to RMB 29.6 million in 2022, mainly due to the procurement of raw materials for the production of self-developed fundus cameras[37] - Cash and cash equivalents decreased from RMB 1,784.6 million in 2021 to RMB 1,268.3 million in 2022, due to investments in financial assets, industrial funds, and operational expenses[39] - Accounts receivable increased from RMB 34.0 million in 2021 to RMB 63.9 million in 2022, with the average turnover days rising from 87 days to 169 days[62] - Contract liabilities increased from RMB 17.1 million in 2021 to RMB 18.2 million in 2022, driven by prepayments from new customer contracts in the second half of 2022[66] - Property, plant, and equipment decreased from RMB 45.0 million as of December 31, 2021, to RMB 33.1 million as of December 31, 2022, primarily due to increased depreciation of hardware equipment[88] - The company is in a net cash position as of December 31, 2022, making the debt-to-asset ratio not applicable[70] - The company has no bank loans or other borrowings as of December 31, 2022 (2021: none)[93] AI and Medical Device Development - The company's AI-based retinal imaging diagnostic product, Airdoc-AIFUNDUS (1.0), is the first AI retinal imaging recognition product to receive a Class III medical device certificate from the National Medical Products Administration[3] - Airdoc-AIFUNDUS (2.0) is expected to submit an application for Class III medical device certification for hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration in Q4 2022[9] - The company's AI diagnostic system (RAIDS) demonstrated a sensitivity of 89.8% in detecting 10 types of retinal diseases, with accuracy ranging from 95.3% to 99.9%[5] - The company's AI-FUNDUSCAMERA-P, a Class II medical device, was approved in March 2021[8] - Airdoc-AIFUNDUS (2.0) completed clinical trials in Q3 2022 and applied for new indications approval in Q4 2022, aiming to become China's first AI-assisted diagnostic SaMD with multiple approved indications[13] - RAIDS demonstrated 89.8% sensitivity in detecting 10 retinal diseases and accuracy ranging from 95.3% to 99.9% in distinguishing them, outperforming human retinal experts[18] - The AI-FUNDUSCAMERA-D, a fully automated desktop fundus camera, received Class II medical device registration from the Shanghai Medical Products Administration in July 2022[42] - The company has developed over 90 deep learning algorithms to cover a wide range of diseases, lesions, and health risks[43] - Airdoc-AIFUNDUS (2.0) expanded its indications to include hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration (AMD), with clinical trials completed in Q3 2022 and registration certificate updates applied for in Q4 2022[177] - AI-FUNDUSCAMERA-D, a fully automated desktop fundus camera, received Class II medical device registration from the Shanghai Medical Products Administration in July 2022, offering high-quality imaging at a lower cost compared to traditional high-end models[178] - The company developed AI-based retinal imaging solutions for early detection, diagnosis, and health risk assessment, covering a wide range of diseases and lesions[197] Health Risk Assessment Solutions - The company completed over 4.3 million tests in 2022 using its SaMD and health risk assessment solutions[8] - The company's health risk assessment solutions cover a wide range of conditions, including retinal abnormalities, cardiovascular abnormalities, and anemia[11] - The company's health risk assessment solutions cover 55 types of lesions and diseases, with plans to expand coverage to include conditions like hyperthyroidism, Graves' eye disease, and dementia[15] - The company's health risk assessment solutions can be sold in health and eye health management scenarios without requiring regulatory approval or registration[199] Customer and Market Expansion - Customer base grew from 244 in 2021 to 397 in 2022, with 2,371 service outlets using SaMD and health risk assessment solutions monthly, despite a 12% YoY decrease in total tests to 4.3 million[20] - The company's solutions served nearly 94 insurance companies, including top commercial insurers, and were used in over 780 pharmacies, with monthly service outlets increasing by over 200% YoY[23] - Revenue from Eagle Health reached RMB 41.8 million during the reporting period[23] - The company achieved solid progress in commercializing its three business pillars: Eagle Eye Medical, Eagle Eye Health, and Eagle Eye Eye Health, with AI-based SaMD, health risk assessment solutions, and hardware devices widely adopted across various health service scenarios[179] - The company established its own factory in Changsha, Hunan, enabling self-controlled production capabilities, and launched a myopia treatment product to diversify its product portfolio[179] Corporate Governance and Leadership - The Board continues to review and oversee operations to maintain high corporate governance standards[83] - The company's board consists of 4 executive directors, 2 non-executive directors, and 3 independent non-executive directors[119] - The company has entered into three-year service agreements with directors Chen Xin, Luo Ting, Wang Lin, and Zhu Tingyao, effective from their respective appointment dates[123] - The company provides professional development training for directors, with costs covered by the company and annual submission of signed training records required[116] - The company has arranged appropriate insurance coverage for directors and senior officers against potential legal liabilities arising from corporate activities, with annual review of coverage[127] - The company ensures compliance with listing rules by maintaining at least three independent non-executive directors, one of whom must have appropriate professional qualifications or accounting/financial management expertise[106] - The company has received annual written confirmations from independent non-executive directors regarding their independence in accordance with listing rules[121] - The company has established four board committees: Audit Committee, Remuneration and Appraisal Committee, Nomination Committee, and Strategy Committee[125] - The company provides updates on listing rules and regulatory developments to directors to ensure compliance with good corporate governance practices[129] - The company's board is responsible for leading and monitoring the company's affairs, providing strategic guidance, and overseeing operational and financial performance[113] - The company's directors are required to participate in continuous professional development to maintain and update their knowledge and skills[114] - Zhang Dalei, aged 40, was appointed as CEO on September 9, 2015, and currently serves as both Chairman and CEO, leveraging his extensive experience in the medical device industry[141] - Yang Wenting, aged 37, joined the company in June 2020 and was appointed as CFO on December 25, 2020, with a background in finance and investment management[133] - The company's board consists of four executive directors, two non-executive directors, and three independent non-executive directors, ensuring a balanced and independent governance structure[141] - The company has adopted the Corporate Governance Code as outlined in Appendix 14 of the Listing Rules to regulate its corporate governance practices[139] - All directors and supervisors confirmed compliance with the standard code regarding securities trading during the reporting period[142] - Newly appointed directors receive necessary onboarding training and information to ensure they understand the company's operations and their legal responsibilities[143] - Wu Gangping, aged 65, was appointed as an independent non-executive director on April 30, 2021, bringing over 30 years of professional experience in the accounting industry[147] - Dr. Wu Yangfeng, aged 60, was appointed as an independent non-executive director on December 25, 2020, with a background in clinical research and epidemiology[148] - The company emphasizes the importance of separating the roles of Chairman and CEO, although currently, both roles are held by Zhang Dalei due to his strategic importance to the company[141] - The company ensures that its senior management and directors are well-informed about legal and regulatory updates relevant to their roles[143] Research and Development - The company collaborated on a study published in Age and Ageing (IF:12.782), the first global research combining AI technology with fundus imaging to identify high-risk dementia populations[19] - The company has developed over 90 deep learning algorithms to cover a wide range of diseases, lesions, and health risks[43] Inventory and Sales Management - Inventory management is closely monitored to maintain optimal levels aligned with near-term usage expectations[89] - Sales cost increased by 28.6% from RMB 44.9 million in 2021 to RMB 57.8 million in 2022, mainly due to higher procurement costs for myopia treatment devices[53] - Sales cost for the year ending December 31 was RMB 57,805 thousand, a decrease from RMB 44,940 thousand in the previous year[174] Treasury and Financial Management - The company adopts a prudent treasury policy to ensure liquidity structure meets funding needs[71] - The company's H-shares were listed on the Main Board of the Hong Kong Stock Exchange on November 5, 2021, under Chapter 18A of the Listing Rules[175] Leadership and Expertise - Zhang Dalei, the founder, has over 13 years of experience in managing high-tech companies and specializes in AI technology R&D[97] - Dr. Chen Yuzhong, responsible for medical R&D and product registration, has over 21 years of experience in applying IT to clinical practice[74] - Chen Hailong, responsible for product structure design and R&D, has over 16 years of experience in the IT industry[101] - Wang Lin, appointed as an executive director in March 2023, has over 12 years of legal practice experience[102]